Hims & Hers Health has undeniably captured market attention and investor enthusiasm, fueled by a successful Super Bowl ad campaign and its strategic entry into the high-demand GLP-1 weight loss ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site. The ad also hit a nerve with the pharma industry, lawmakers and some industry groups. The ad ...

Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticized the American ...

Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...

Earlier in February, Hims & Hers Health rallied as it was set to debut its controversial Super Bowl ad, where it positioned itself as the “affordable, doctor-trusted, formulated in the US ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...

Shares of Hims & Hers Health ( HIMS) tumbled 15% yesterday after Novo Nordisk (NVO) announced it was cutting the price of its ...

Shares of Hims & Hers (HIMS) are down $3.47, or 8%, to $37.50 in pre-market trading after a court denied a motion for a preliminary ...